Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014891 | 1.00 | MAPT (0.35) | MAPTCES2CES1 | |
| SCHEMBL1016151 | 0.97 | CES2 (0.39) | MAPTCES2CES1 | |
| SCHEMBL1016150 | 0.97 | CES2 (0.39) | MAPTCES2CES1 | |
| SCHEMBL1014910 | 0.95 | CES2 (0.42) | MAPTCES2CES1 | |
| SCHEMBL1014911 | 0.95 | CES2 (0.42) | MAPTCES2CES1 | |
| SCHEMBL1015828 | 0.93 | MAPT (0.36) | MAPT | |
| SCHEMBL1015830 | 0.93 | MAPT (0.36) | MAPT | |
| SCHEMBL31587724 | 0.93 | MAPT (0.36) | MAPT | |
| SCHEMBL21960394 | 0.85 | RECQL (0.39) | MAPT | |
| SCHEMBL28228568 | 0.82 | CYP2C9 (0.44) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210093613-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-10744118-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10342781-B2 | Diazole amides | CHEMOCENTRYX, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180071257-A1 | DIAZOLE AMIDES | CHEMOCENTRYX, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071257-A1 | DIAZOLE AMIDES | CHEMOCENTRYX, INC. | 2018-03-15 | — | — | US | disclosed |
| EP-2935227-B1 | DIAZOLE AMIDES AS CCR1 RECEPTOR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9750722-B2 | Diazole amides | CHEMOCENTRYX, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750722-B2 | Diazole amides | CHEMOCENTRYX, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| WO-2011049520-A1 | ADAMANTYL IMINOCARBONYL-SUBSTITUTED PYRIMIDINES AS INHIBITORS OF 1 1 BETAHSD1 | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | MAPT 4375/4885CES2 297/4885CES1 79/4885 |
| US-20180071257-A1 | DIAZOLE AMIDES | CCR1, CCRL2, CCR4 | MAPT 4285/4885CES2 245/4885CES1 115/4885 |
| US-20210093613-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | MAPT 4450/4885CES2 203/4885CES1 128/4885 |
| US-10342781-B2 | Diazole amides | CCR1, CCRL2, CCR4 | MAPT 4285/4885CES2 245/4885CES1 115/4885 |
| US-10744118-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | MAPT 4450/4885CES2 203/4885CES1 128/4885 |
| US-11759454-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | MAPT 4450/4885CES2 203/4885CES1 128/4885 |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | HSD11B1, HSD17B11, HSD3B1 | MAPT 3552/4885CES2 794/4885CES1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.